Advertisement

Medical Oncology

, 34:178 | Cite as

Theoretical method for evaluation of therapeutic effects and adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors in clinical treatment

  • Koji Kimura
  • Risa Takayanagi
  • Tomoki Fukushima
  • Yasuhiko Yamada
Original Paper

Abstract

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used for non-small cell lung cancer patients with an EGFR gene mutation. However, skin disorders are known as adverse events. In the present study, we investigated whether EGFR-TK occupancy is useful as an index for assessing clinical efficacy and adverse events for the proper use and development of EGFR-TKIs. Average binding occupancies (Φ ss) of EGFR-TKIs, gefitinib and erlotinib, for the EGFR-TK of cancer or skin cells were calculated. The relationships of Φ ss with response rate (RR) or frequency of rash were analyzed using the ternary complex model. Then, the relationships between the dose of EGFR-TKIs and RR or frequency of rash were examined. Gefitinib showed a greater difference for Φ ss value for both wild-type and mutant EGFR as compared to erlotinib at usual dose. The RR increased in a nonlinear manner rapidly rising when Φ ss exceeded 95%. It was thought that a very high Φ ss value might be needed to obtain the therapeutic effect of EGFR-TKIs. Meanwhile, the frequency of rash increased in a linear manner along with elevation of Φ ss. It was shown that the K d ratio (K d for mutant/K d for wild type) was less than 0.001, when the high RR and low frequency of rash were obtained simultaneously. The results showed that the therapeutic effects and skin disorder can be assessed by using Φ ss. Furthermore, it is likely that a proper choice of drug and dose can be made by using Φ ss in EGFR-TKI therapy.

Keywords

Gefitinib Erlotinib Non-small cell lung cancer Response rate Rash Target molecular binding occupancy 

Notes

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

None.

References

  1. 1.
    Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67. doi: 10.1056/NEJMoa0904554.CrossRefPubMedGoogle Scholar
  2. 2.
    Yamamoto N, Honma M, Suzuki H. Off-target serine/threonine kinase 10 inhibition by erlotinib enhances lymphocytic activity leading to severe skin disorders. Mol Pharmacol. 2011;80(3):466–75. doi: 10.1124/mol.110.070862.CrossRefPubMedGoogle Scholar
  3. 3.
    Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA. 2008;105(6):2070–5. doi: 10.1073/pnas.0709662105.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N, Nishio K. In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib. Biochem J. 2006;397(3):537–43. doi: 10.1042/BJ20051962.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Can Res. 2006;66(16):8163–71. doi: 10.1158/0008-5472.CAN-06-0453.CrossRefGoogle Scholar
  6. 6.
    Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer J. 2006;118(2):257–62. doi: 10.1002/ijc.21496.CrossRefGoogle Scholar
  7. 7.
    Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39. doi: 10.1056/NEJMoa040938.CrossRefPubMedGoogle Scholar
  8. 8.
    Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Can Res. 2004;64(18):6652–9. doi: 10.1158/0008-5472.CAN-04-1168.CrossRefGoogle Scholar
  9. 9.
    Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8. doi: 10.1056/NEJMoa0909530.CrossRefPubMedGoogle Scholar
  10. 10.
    Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57. doi: 10.1056/NEJMoa0810699.CrossRefPubMedGoogle Scholar
  11. 11.
    Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97(9):643–55. doi: 10.1093/jnci/dji112.CrossRefPubMedGoogle Scholar
  12. 12.
    Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol. 2005;16(7):1081–6. doi: 10.1093/annonc/mdi221.CrossRefPubMedGoogle Scholar
  13. 13.
    Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2010;28(5):744–52. doi: 10.1200/JCO.2009.24.3030.CrossRefPubMedGoogle Scholar
  14. 14.
    Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006;24(31):5034–42. doi: 10.1200/JCO.2006.06.3958.CrossRefPubMedGoogle Scholar
  15. 15.
    Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2005;23(11):2493–501. doi: 10.1200/JCO.2005.01.388.CrossRefPubMedGoogle Scholar
  16. 16.
    Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res. 2004;10(24):8195–203. doi: 10.1158/1078-0432.CCR-04-1245.CrossRefPubMedGoogle Scholar
  17. 17.
    Kim KS, Jeong JY, Kim YC, Na KJ, Kim YH, Ahn SJ, et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res. 2005;11(6):2244–51. doi: 10.1158/1078-0432.CCR-04-2081.CrossRefPubMedGoogle Scholar
  18. 18.
    Kondo M, Yokoyama T, Fukui T, Yoshioka H, Yokoi K, Nagasaka T, et al. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. Lung Cancer. 2005;50(3):385–91. doi: 10.1016/j.lungcan.2005.06.008.CrossRefPubMedGoogle Scholar
  19. 19.
    Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol. 2008;26(26):4244–52. doi: 10.1200/JCO.2007.15.0185.CrossRefPubMedGoogle Scholar
  20. 20.
    Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23(11):2513–20. doi: 10.1200/JCO.2005.00.992.CrossRefPubMedGoogle Scholar
  21. 21.
    Mu XL, Li LY, Zhang XT, Wang MZ, Feng RE, Cui QC, et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Clin Cancer Res. 2005;11(12):4289–94. doi: 10.1158/1078-0432.CCR-04-2506.CrossRefPubMedGoogle Scholar
  22. 22.
    Niho S, Kubota K, Goto K, Yoh K, Ohmatsu H, Kakinuma R, et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 2006;24(1):64–9. doi: 10.1200/JCO.2005.02.5825.CrossRefPubMedGoogle Scholar
  23. 23.
    Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500. doi: 10.1126/science.1099314.CrossRefPubMedGoogle Scholar
  24. 24.
    Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101(36):13306–11. doi: 10.1073/pnas.0405220101.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Rosell R, Gervais R, Vergnenegre A, Massuti B, Felip E, Cardenal F, Garcia Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Di Seri M, Garrido Lopez P, Insa A, De Marinis F, Corre R, Carreras M, Carcereny E, Taron M, Paz-Ares LG and Spanish Lung Cancer Group, editor. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. ASCO Annual Meeting Abstracts Part 1; 2011 May 20. vol 15_suppl.; Chicago, IL, USA: Journal of Clinical Oncology, p 7503.Google Scholar
  26. 26.
    Rosell R, Ichinose Y, Taron M, Sarries C, Queralt C, Mendez P, et al. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer. 2005;50(1):25–33. doi: 10.1016/j.lungcan.2005.05.017.CrossRefPubMedGoogle Scholar
  27. 27.
    Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23(28):6829–37. doi: 10.1200/JCO.2005.01.0793.CrossRefPubMedGoogle Scholar
  28. 28.
    Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res. 2005;11(16):5878–85. doi: 10.1158/1078-0432.CCR-04-2618.CrossRefPubMedGoogle Scholar
  29. 29.
    Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res. 2005;11(3):1167–73.PubMedGoogle Scholar
  30. 30.
    Tomizawa Y, Iijima H, Sunaga N, Sato K, Takise A, Otani Y, et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res. 2005;11(19 Pt 1):6816–22. doi: 10.1158/1078-0432.CCR-05-0441.CrossRefPubMedGoogle Scholar
  31. 31.
    Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353(2):133–44. doi: 10.1056/NEJMoa050736.CrossRefPubMedGoogle Scholar
  32. 32.
    Zhang XT, Li LY, Mu XL, Cui QC, Chang XY, Song W, et al. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol. 2005;16(8):1334–42. doi: 10.1093/annonc/mdi340.CrossRefPubMedGoogle Scholar
  33. 33.
    Zhou C, WU Y, Chen G, Feng J, Liu X, Wang C, Zhang S, Wang J, Zhou S, Ren S, editor. Efficacy results from the randomised phase III optimal (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (PTS) with EGFR activating mutations. Paper presented at 35th ESMO Congress; 2010 8–12 October 2010. vol 6; Milan: Ann Oncol.Google Scholar
  34. 34.
    Togashi Y, Hayashi H, Nakagawa K, Nishio K. Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence. Drug Des Devel Ther. 2014;8:1037–46. doi: 10.2147/DDDT.S50358.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1. J Clin Oncol. 2004;22(5):777–84. doi: 10.1200/JCO.2004.08.001.CrossRefPubMedGoogle Scholar
  36. 36.
    Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2. J Clin Oncol. 2004;22(5):785–94. doi: 10.1200/JCO.2004.07.215.CrossRefPubMedGoogle Scholar
  37. 37.
    Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809–18. doi: 10.1016/S0140-6736(08)61758-4.CrossRefPubMedGoogle Scholar
  38. 38.
    Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol. 2008;26(6):863–9. doi: 10.1200/JCO.2007.13.2720.CrossRefPubMedGoogle Scholar
  39. 39.
    Maeda N, Sarumaru T, Kijima A, Yoshida N, Nishino H, Kataoka Y, Hirajima T. Cutaneous toxicities in patients treated with erlotinib (Tarceva), an inhibitor of the epidermal growth factor receptor. Mag Jpn Dermatol Assoc. 2010;120(10):2039–49. doi: 10.14924/dermatol.120.2039.Google Scholar
  40. 40.
    Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22(16):3238–47. doi: 10.1200/JCO.2004.11.057.CrossRefPubMedGoogle Scholar
  41. 41.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–32. doi: 10.1056/NEJMoa050753.CrossRefPubMedGoogle Scholar
  42. 42.
    Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527–37. doi: 10.1016/S0140-6736(05)67625-8.CrossRefPubMedGoogle Scholar
  43. 43.
    Yamada Y, Matsuyama K, Ito K, Sawada Y, Iga T. Risk assessment of adverse pulmonary effects induced by adrenaline beta-receptor antagonists and rational drug dosage regimen based on receptor occupancy. J Pharmacokinet Biopharm. 1995;23(5):463–78.CrossRefPubMedGoogle Scholar
  44. 44.
    Miyazaki S. Clinical study of the epidermal growth factor contents in urine, plasma and tissue from the patients with urological diseases. Hinyokika kiyo Acta urologica Japonica. 1992;38(8):919–24.PubMedGoogle Scholar
  45. 45.
    Maly IV, Wiley HS, Lauffenburger DA. Self-organization of polarized cell signaling via autocrine circuits: computational model analysis. Biophys J. 2004;86(1 Pt 1):10–22.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Department of Clinical Evaluation of Drug Efficacy, School of PharmacyTokyo University of Pharmacy and Life SciencesHachiojiJapan

Personalised recommendations